Floatz logo

Linvoseltamab

Smoldering Multiple Myeloma (SMM)

Regeneron PharmaceuticalsPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Smoldering Multiple Myeloma (SMM) cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Regeneron Pharmaceuticals
Phase 3BB
FILGRASTIM
Regeneron Pharmaceuticals
Phase 3BB
cc-5013
Irene Ghobrial, MD
Phase 3BB
DARATUMUMAB
Regeneron Pharmaceuticals
Phase 3BB
Cyclophosphamide
Dana-Farber Cancer Institute
Phase 2B

View all 48 →

Same molecule, other indications

Linvoseltamab is also rated in:

plasma cell myelomaDormant
BB
Indicative ·
66 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
65 / 100
View asset →
monoclonal gammopathy of uncertain significanceDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →